From: Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments
Attributes
Levels
Progression free survival (PFS)
2, 8, 14 months
Anemia
0, 3, 6 %
Pneumonitis
0, 2, 4 %
Monthly cost
0, US$3030.3, US$6060.6a